Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086775
Status:
COMPLETED
Last Update Posted:
2013-08-02
First Post:
2004-07-08
Brief Title:
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
Sponsor:
Bayer
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
BRLX-FLUCAM106
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Bayer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None